Bentham Science Media Partnership | The 2nd Saudi International Pharma Expo

 

SIPE 2019 will provide an opportunity for the participating companies to display their products & services to the gamut of visitors, globally from pharma and healthcare industries. The 3-day expo will bring together eminent personalities from various sectors of pharma, non-pharma and healthcare industries. SIPE 2018 is aimed at bringing together all the pharma professionals under one roof, the pharmaceutical exhibition focused on knowledge, technology and business development.

SIPE 2019 is one stop juncture to all those who are planning to expand their business through various channels of franchise and distribution. will showcase the latest trends and technologies in pharmaceuticals, drugs and formulations; direct access to highly target senior pharma executives, buyers, procurement managers, contract manufacturers, hospital administration and many more.

 

Pharma post.jpg

Bentham Science Media Partnership | The 2nd SAUDI INTERNATIONAL Medlab EXPO 2019

 

The 2nd SAUDI INTERNATIONAL Medlab EXPO 2019 brings together leading laboratory experts, scientists, researchers and clinicians to exchange and share their experiences and research results on all aspects of laboratory medicine and clinical research.

Exhibiting at The 2nd SAUDI INTERNATIONAL Medlab EXPO 2019  provides an exceptional combination of networking and corporate branding opportunities are perfect opportunity to boost your company’s profile.

It will bring together the leaders in the medical laboratory industry at an event designed to create maximum interaction and meeting opportunities where manufacturers, dealers and distributors can promote their brands, meet potential customers and entertain existing clients.

 

Medlab post

Aims & Scope | Letters in Organic Chemistry 

Letters in Organic Chemistry publishes original letters (short articles), research articles, full-length/mini-reviews and thematic issues based on mini-reviews and short articles, in all areas of organic chemistry including synthesis, bioorganic, medicinal, natural products, organometallic, supramolecular, molecular recognition and physical organic chemistry. The emphasis is to publish quality papers rapidly by taking full advantage of latest technology for both submission and review of the manuscripts.

The journal is an essential reading for all organic chemists belonging to both academia and industry. To learn more about the journal, please visit: https://benthamscience.com/journals/letters-in-organic-chemistry/

 

loc-flyer.jpg

The Queensland University of Technology | Inhaled nanoparticles could treat lung cancer

 

Lung cancer sufferers could one day inhale targeted chemotherapy via chitosan nanoparticles, replacing intravenous and oral delivery with a non-invasive, lower dose and better uptake by the body method.

  • Delivering drugs via an inhaler into the lungs is the subject of research around the world
  • Dry powder inhalation of drugs promises a non-invasive, lower dose and better absorption method
  • Chitosan, made from crustacean shells, is biodegradable and is being investigated as a carrier for chemotherapy for lung cancer

https://www.qut.edu.au/news?id=142188

 

QUT pharmaceutical scientist Dr Nazrul Islam, from School of Clinical Sciences, said lung cancer was one of the most common cancers globally and one of the deadliest, being a leading cause of cancer deaths.

He said chitosan had long been investigated for drug delivery and medical applications. It is made from refined crustacean (prawns, crabs, lobster) shells and was an abundant and cheap polymer.

 “Drug delivery directly into the lungs via an inhaler is an efficient way to achieve local and systemic effects of medications,” Dr Islam said.

 

 

“My research is concerned with dry powder inhalation using chitosan nanoparticles loaded with drugs that can reach the lower respiratory tract and from there diffuse into the bloodstream.

“Chitosan is a natural polymer that is known as biodegradable and biocompatible (ie human-cell friendly) and has low toxicity and it can be bound with therapeutic drugs and made into nanoparticles.

“We use different chemical agents called cross-linkers to help form chitosan nanoparticles in which we incorporate drugs, and our concern is whether chitosan nanoparticles formed with some cross-linkers are biodegradable or not.

 “As yet, no studies have conclusively shown complete biodegradation or elimination of chitosan nanoparticles in lung tissue and my research is concerned with finding the form of chitosan that is able to biodegrade in the lungs’ unique tissues.”

Dr Islam said many scientists were investigating the delivery of chemotherapy drugs via the lungs.

 

 

“While many studies have looked at the use of lung delivery of drugs including chemotherapy, gene therapy, vaccines and immunotherapy, none, to my knowledge, has exclusively looked at chitosan as a safe carrier for lung drug delivery,” he said.

 “The reason we study chitosan is also because it has mucoadhesive properties which means it sticks to the lining of the lung cells and it has been found to improve the absorption of therapeutic agents by opening the junctions between cells of the lung lining to allow the drug to target cancer cells.

“Targeted delivery of drugs increases the target tissues’ exposure to the drug while reducing exposure of healthy cells and organs to that drug, which means less toxicity and fewer side-effects.”

Dr Islam said much research suggested chitosan-based nanoparticle drug delivery could be the way of the future to deliver drugs for many different conditions besides lung cancer.

 “We need more research to understand the real-life degradation of chitosan, and identify degradation products and their possible toxicities in the body before we can conduct human trials.

 

 

“We believe chitosan-based nanoparticulate drug delivery has the potential to deliver a large number of therapeutic agents to treat various diseases and open a new era for chitosan-based materials for lung drug delivery and other medical purposes.”

Inhaled micro/nanoparticulate anticancer drug formulations: An emerging targeted drug delivery strategy for lung cancers was published in Current Cancer Drug Targets.

 

 

Most Accessed Articles | Synthesis and Biological Evaluation of PF-543 Derivative

 

Journal Name: Letters in Organic Chemistry

Author(s): Seon Woong Kim, Taeho Lee, Joo-Youn Lee, Sanghee Kim, Hee-Sook Jun, Eun-Young Park*, Dong Jae Baek*.

 

Wordpressm

PF-543 has been known as a substance that strongly inhibits SK1. However, it also exhibits antineoplastic activity that is lower than other inhibitors of SK1. In this study, we compared PF-543 and synthesized a newly designed derivative of PF-543 (compound 2) in which two aromatic structures were connected in para-form. The synthesized derivative showed inhibitory effect on SK1, similar to that of PF-543. However, it was more cytotoxic to HT29, AGS, and PC3 cells than PF-543. We also carried out a docking study for SK1 and demonstrated that the synthesized derivative showed interaction with SK1 similar to PF-543. Results obtained from this study suggest that the structure of compound 2 may be well substituted for the structure of PF-543 in terms of biological activity, providing us important structural information for the design of new derivatives of PF-543. Read out full article here: http://www.eurekaselect.com/166082

 

Open Access Articles | Synthesis of 1-(3-Phenylpropyl)-4-(pyridinylmethoxy)-[1,2,4]triazolo[4,3-a] quinoxalines

 

Journal Name: Letters in Organic Chemistry

Author(s): Dominik Summer, Barbara Matuszczak*.

 

 

Starting from 2,3-dichloroquinoxaline, a synthetic strategy for the preparation of 1-(3- phenylpropyl)-4-(pyridinylmethoxy)[1,2,4]triazolo[4,3-a]quinoxalines is described. Read out full article here:  http://www.eurekaselect.com/163737

 

Wordpress

 

 

 

New Issue | Current Topics in Medicinal Chemistry; Volume: 19, Issue: 6

 

Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.

 

ctmc.jpg

 

Articles from the journal: Current Topics in Medicinal Chemistry; Volume: 19, Issue: 6

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/615/current-topics-in-medicinal-chemistry/issue/19/2599/6/9078

 

 

 

Press Release | Treatment of Parkinson’s disease: Separating hope from hype

 

Parkinson’s disease is a neurodegenerative disorder characterized by motor and nonmotor deficits majorly caused by the loss of dopaminergic cells in the Substantia Nigra pars compacta (SNc) as well as the destruction of nigrostriatal pathway. Despite the numerous advances in cutting-edge approaches for the treatment or prevention of PD, there still exists some obstacles that have incapacitated the definitive treatment of this disease.

New therapeutic strategies have emerged over recent years to treat PD, including gene- and stem cell- based therapies, targeted delivery of neurotrophic factors, and brain stimulation techniques such as Transcranial Magnetic Stimulation (TMS), transcranial Direct Current Stimulation (tDCS), and Deep Brain Stimulation (DBS).

The review covers various gene therapy strategies including Adeno-Associated Virus-Glutamic Acid Decarboxylase (AAV-GAD), AAV-Aromatic L-Amino Acid Decarboxylase (AAV-AADC), Lenti-AADC/Tyrosine Hydroxylase/Guanosine Triphosphate- Cyclohydrolase I (Lenti-AADC/TH/GTP-CH1), AAV-Neurturin (AAV-NRTN), α-Synuclein silencing, and PRKN gene delivery. The review also covers the advantages and disadvantages of these treatments along with the results of relevant trials. With many advances in treatments for PD, there still exist some hurdles that have resulted in treatment failure; the reasons for failure of treatment were described, with hope separated from hype. Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2018-12/bsp-top122618.php

 

Wordpress

 

The article by Dr. Alireza Mohammadi et al. is published in Current Gene Therapy, Volume 18, Issue 4, 2018. To obtain the article please visit: http://www.eurekaselect.com/165253

 

 

CALL FOR PAPERS | Thematic Issue for Current Medicinal Chemistry

 

Journal: Current Medicinal Chemistry

 

Guest Editor(s)Alexandru Mihai GRUMEZESCU
Tentative Publication Date: June, 2019

 

“REGENERATIVE MEDICINE AND TISSUE ENGINEERING”

Biomimetic scaffold which can mimic the native extracellular matrices have been developed by many research groups in order to improve the cell-scaffold interactions and to reach a new level of biocompatibility. These recent developments in the tissue construction area have lead to the idea that organ fabrication can be possible by using the available production techniques in combination with cells and growth factors to restore the function of an affected organ and even to increase the transplantation rate. Combining all those parameters together with the human body’s potential to heal in a proper environment, many products can be developed in order to diagnose and treat critical diseases from an early stage and to undertake the biggest crisis reported at the moment. The aim of this special issue is to present the latest updates in the field. For more details please visit: https://bit.ly/2LIe8PF

 

Email here to submit your paper: hermain@benthamscience.net

                                                          CC: faizan@benthamscience.net

 

thematic flyer cmc

Become an Editorial Board Member (EBM) | Current Medicinal Chemistry

 

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Abstracted and Indexed in:

  • Science Citation Index®
  • Journal Citation Reports/Science Edition
  • InCites
  • Science Citation Index Expanded
  • Index to Scientific Reviews®
  • Biochemistry and Biophysics Citation Index®
  • Current Contents® – Life Sciences
  • Research Alert
  • BIOSIS
  • BIOSIS Previews
  • BIOSIS Reviews Reports and Meetings
  • Prous Science Integrity®
  • MEDLINE/PubMed/Index Medicus
  • Scopus
  • EMBASE/Excerpta Medica
  • Chemical Abstracts Service/SciFinder
  • ProQuest
  • ChemWeb
  • Google Scholar
  • BIOBASE
  • Reference Update
  • PubsHub
  • Index Copernicus
  • MediaFinder®-Standard Periodical Directory
  • Genamics JournalSeek
  • J-Gate
  • CNKI Scholar
  • Suweco CZ
  • TOC Premier
  • EBSCO
  • British Library
  • Ulrich’s Periodicals Directory
  • JournalTOCs

The Journal Current Medicinal Chemistry is interested in appointing active Editorial Board Member  on the Journal’s Board. If you are working in the mentioned field of the journal and are interested in becoming an Editorial Board Member, please send us your CV and a list of publications. If, however, the scope of the journal is not directly related to your field of interest, please feel free to recommend suitable colleagues for the said position and, if possible, send us their CV along with their list of publications. Mention in the subject line, the field of interest and send your CV at:

 

Wordpress.jpg

%d bloggers like this: